ANDAINJECTIONINJECTABLE
Approved
Jul 2017
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PHENTOLAMINE MESYLATE (phentolamine mesylate) by Precision BioSciences is clinical pharmacology phentolamine mesylate for injection, usp produces an alpha-adrenergic block of relatively short duration. First approved in 2017.
Drug data last refreshed 18h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Phentolamine Mesylate for Injection, USP produces an alpha-adrenergic block of relatively short duration. It also has direct, but less marked, positive inotropic and chronotropic effects on cardiac muscle and vasodilator effects on vascular smooth muscle. Phentolamine Mesylate…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Worked on PHENTOLAMINE MESYLATE at Precision BioSciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.